Tove Tuntland

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

Jianming Zhang, Francisco Adrián, Wolfgang Jahnke et al. · Nature · 2010 · 590 citations

Molecular Pharmacology, Drug Target, Medicine +5

Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness

Shilpi Khare, A. S. Nagle, Agnes Biggart et al. · Nature · 2016 · 407 citations · Full text

Proteasome Inhibition, Medicinal Chemistry, Antiparasitic Agent +11

Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-<i>N</i>2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-<i>N</i>4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

Thomas H. Marsilje, Wei Pei, Bei Chen et al. · Journal of Medicinal Chemistry · 2013 · 405 citations · Full text

Chemoprevention Strategy, Pharmacotherapy, Structure–activity Relationships +21

Imaging of <i>Plasmodium</i> Liver Stages to Drive Next-Generation Antimalarial Drug Discovery

Stephan Meister, David Plouffe, Kelli Kuhen et al. · Science · 2011 · 347 citations · Full text

Antiparasitic Agent, Malaria, Pathology +16

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist

Shifeng Pan, Xu Wu, Jiqing Jiang et al. · ACS Medicinal Chemistry Letters · 2010 · 325 citations · Full text

Selective Smoothened Antagonist, Chemoprevention Strategy, Novel Therapy +14